A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A SINGLE ADMINISTRATION OF COMP360 IN PARTICIPANTS WITH TREATMENT-RESISTANT DEPRESSION

Registry ID

COMP 006

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

COMPASS PATHFINDER LIMITED

Start date

2023-09-13

Last update

2023-06-22

Conditions

• DEPRESSION

Related clinical trials

• CLINICAL TRIAL PROTOCOL TITLE: EVALUATING THE ROLE OF PSILOCYBIN MONITORS IN PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION: A PILOT RANDOMIZED CLINICAL TRIAL
• INTRAVENOUS KETAMINE AND IMMERSIVE VIRTUAL REALITY TO TREAT DEPRESSION (TREASURE TRIAL): A PILOT, RANDOMIZED CONTROLLED TRIAL
• ENGAGING MOOD BRAIN CIRCUITS WITH PSILOCYBIN: A RANDOMIZED NEUROIMAGING TRIAL IN DEPRESSION
• PSILOCYBIN-ASSISTED EXISTENTIAL, ATTACHMENT AND RELATIONAL (PEARL) THERAPY FOR CAREGIVERS OF PATIENTS WITH ADVANCED CANCER: A PHASE II OPEN-LABEL TRIAL
• RAPID REVERSAL OF SUICIDAL DEPRESSION: COMPARATIVE EFFECTIVENESS OF ECT VS. KETAMINE OVER THE LIFESPAN (REAKT-SD)
• PSILOCYBIN-ASSISTED PSYCHOTHERAPY FOR TREATMENT-RESISTANT DEPRESSION: A RANDOMIZED PHASE II CLINICAL TRIAL COMPARING ONE VERSUS TWO PSYCHEDELIC DOSES OF PSILOCYBIN (PSI-1V2)

View on source registry